Aortic valve stenosis (AVS) is the most common primary valve disease and AVS is associated with high mortality. Especially in eldery patients with an increased surgical risk, transcatheter aortic valve replacement (TAVR) offers several advantages compared to surgical aortic valve replacement, the current standard of care. Nevertheless, there is a high risk of atherothrombotic complications such as stroke in the first months after TAVR.
With this study, the team aims to establish a hemostatic profile for patients after TAVR. The aim is to evaluate new biomarkers by various analyzes of blood samples. These markers will be used to identify patients with an increased risk for thrombotic or bleeding events to enable a personalized antithrombotic therapy.
Here you can find further information.